Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lewy Bodies Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT02524405
What this trial is testing

BEAM: Brain-Eye Amyloid Memory Study

Who this might be right for
Alzheimer's DiseaseMild Cognitive ImpairmentVascular Cognitive Impairment+2 more
Sunnybrook Health Sciences Centre 345
Testing effectiveness (Phase 2)Active Not RecruitingNCT04626479
What this trial is testing

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 400
Large-scale testing (Phase 3)Study completedNCT02252042
What this trial is testing

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Who this might be right for
Head and Neck Squamous Cell Cancer
Merck Sharp & Dohme LLC 495
Not applicableStudy completedNCT03648905
What this trial is testing

Clinical Laboratory Evaluation of Chronic Autonomic Failure

Who this might be right for
Parkinson's DiseaseMultiple System AtrophyAutonomic Failure
National Institute of Neurological Disorders and Stroke (NINDS) 89
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableStudy completedNCT06900686
What this trial is testing

Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival

Who this might be right for
Rectal CancerColon Cancer
Yanhong Deng 458
Not applicableLooking for participantsNCT04724941
What this trial is testing

Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

Who this might be right for
Parkinson Disease
University Hospital Schleswig-Holstein 2,000
Not applicableStudy completedNCT05384353
What this trial is testing

In Vivo PET of Synaptic Density in Cognitive Disorders

Who this might be right for
Alzheimer DiseaseFrontotemporal DegenerationDementia With Lewy Bodies+1 more
Universitaire Ziekenhuizen KU Leuven 134
Not applicableStudy completedNCT04748666
What this trial is testing

PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia

Who this might be right for
Alzheimer DiseaseFrontotemporal Degeneration (FTD)Lewy Body Dementia (LBD)+3 more
University of Texas Southwestern Medical Center 94
Testing effectiveness (Phase 2)Study completedNCT05342636
What this trial is testing

Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
Merck Sharp & Dohme LLC 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT04995523
What this trial is testing

AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Who this might be right for
Non-Small-Cell Lung Carcinoma
AstraZeneca 212
Testing effectiveness (Phase 2)Study completedNCT04002674
What this trial is testing

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Who this might be right for
Dementia With Lewy Bodies
Georgetown University 43
Early research (Phase 1)Study completedNCT03010176
What this trial is testing

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Who this might be right for
Solid TumorsLymphoma
Merck Sharp & Dohme LLC 156
Large-scale testing (Phase 3)Study completedNCT05298423
What this trial is testing

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 610
Testing effectiveness (Phase 2)Study completedNCT03664024
What this trial is testing

Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)

Who this might be right for
Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 118
Post-approval studies (Phase 4)Enrolling By InvitationNCT00950430
What this trial is testing

Imaging of Brain Amyloid Plaques in the Aging Population

Who this might be right for
Alzheimer's DiseaseDementia With Lewy BodiesFrontotemporal Dementia+1 more
Mayo Clinic 8,000
Testing effectiveness (Phase 2)Study completedNCT04704219
What this trial is testing

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 160
Not applicableUnknownNCT06246019
What this trial is testing

The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers

Who this might be right for
Alzheimer DiseaseCognitive ImpairmentDementia+4 more
Hospital del Mar Research Institute (IMIM) 200
Testing effectiveness (Phase 2)Looking for participantsNCT07589595
What this trial is testing

Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Who this might be right for
Cognitive DysfunctionLewy Body DiseaseSynucleinopathies+1 more
Eli Lilly and Company 350
Early research (Phase 1)Study completedNCT06460961
What this trial is testing

MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Who this might be right for
Neoplasm Metastasis
Merck Sharp & Dohme LLC 40
Next Page